HHealthcare Read More Novo Nordisk and Omeros announce asset purchase and licenseOctober 15, 2025 Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk’s Rare Disease…
HHealth Read More Novo Nordisk’s Wegovy® cuts risk of heart attack, stroke orAugust 31, 2025 Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater reduction in the risk of heart…